Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study
Abstract Background Epidermal growth factor receptor (EGFR) amplification refers to the copy number increase of EGFR gene, and is often identified as a “bypass” way of Epidermal growth factor receptor Tyrosine kinase inhibitors (EGFR-TKI) resistance. We aimed to explore the effect of EGFR amplificat...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-10390-0 |
| _version_ | 1798005045250228224 |
|---|---|
| author | Duanyang Peng Pingan Liang Congying Zhong Peng Xu Yanqing He Yuxi Luo Xia Wang Anwen Liu Zhimin Zeng |
| author_facet | Duanyang Peng Pingan Liang Congying Zhong Peng Xu Yanqing He Yuxi Luo Xia Wang Anwen Liu Zhimin Zeng |
| author_sort | Duanyang Peng |
| collection | DOAJ |
| description | Abstract Background Epidermal growth factor receptor (EGFR) amplification refers to the copy number increase of EGFR gene, and is often identified as a “bypass” way of Epidermal growth factor receptor Tyrosine kinase inhibitors (EGFR-TKI) resistance. We aimed to explore the effect of EGFR amplification on EGFR mutation treatment-naive advanced non-squamous non-small cell lung cancer (NSCLC) patients. Methods We conducted a prospective observational study in single center, enrolling advanced non-squamous NSCLC patients receiving Tyrosine kinase inhibitors (TKIs) between March 3, 2019, and February 1, 2022. Next-generation sequencing (NGS) was used to detect genetic alterations in tumor tissue samples. Progression-free survival (PFS) curves were performed using the Kaplan-Meier method. Univariate and multivariate analyses were used to evaluate factors affecting the efficacy of TKIs. Results A total of 117 treatment-naive advanced NSCLC patients were identified in this study. EGFR amplification was found in 22 of 117 (18.8%) patients with EGFR mutations. Of 22 patients with EGFR amplification, 10 patients harbored EGFR 19 del, 11 patients with 21-L858R. The median follow-up time was 22.47 months. The median PFS of the patients with or without EGFR amplification was 8.25 months and 10.67 months, respectively (log-rank test, P = 0.63). In multivariate analysis, EGFR amplification was not an independent prognosis factor for the patients receiving first-line TKIs [HR = 1.38, 95%CI (0.73–2.58), P = 0.321]. Subgroup analysis revealed that EGFR amplification is a risk factor for progression in the brain metastasis population. [HR = 2.28, 95%CI (1.01, 5.14), P = 0.047]. Conclusion EGFR amplification is not an independent prognosis factor for PFS in advanced non-squamous NSCLC patients receiving first-line TKIs. However, it is an independent risk factor for PFS in the brain metastasis population. |
| first_indexed | 2024-04-11T12:34:08Z |
| format | Article |
| id | doaj.art-0e871dac4b59454abf30f49efe75964b |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-11T12:34:08Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-0e871dac4b59454abf30f49efe75964b2022-12-22T04:23:41ZengBMCBMC Cancer1471-24072022-12-0122111010.1186/s12885-022-10390-0Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational studyDuanyang Peng0Pingan Liang1Congying Zhong2Peng Xu3Yanqing He4Yuxi Luo5Xia Wang6Anwen Liu7Zhimin Zeng8Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang UniversityDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang UniversityDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang UniversityDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang UniversityDepartment of Nosocomial Infection Control, The Second Affiliated Hospital of Nanchang UniversityDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang UniversityDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang UniversityDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang UniversityDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang UniversityAbstract Background Epidermal growth factor receptor (EGFR) amplification refers to the copy number increase of EGFR gene, and is often identified as a “bypass” way of Epidermal growth factor receptor Tyrosine kinase inhibitors (EGFR-TKI) resistance. We aimed to explore the effect of EGFR amplification on EGFR mutation treatment-naive advanced non-squamous non-small cell lung cancer (NSCLC) patients. Methods We conducted a prospective observational study in single center, enrolling advanced non-squamous NSCLC patients receiving Tyrosine kinase inhibitors (TKIs) between March 3, 2019, and February 1, 2022. Next-generation sequencing (NGS) was used to detect genetic alterations in tumor tissue samples. Progression-free survival (PFS) curves were performed using the Kaplan-Meier method. Univariate and multivariate analyses were used to evaluate factors affecting the efficacy of TKIs. Results A total of 117 treatment-naive advanced NSCLC patients were identified in this study. EGFR amplification was found in 22 of 117 (18.8%) patients with EGFR mutations. Of 22 patients with EGFR amplification, 10 patients harbored EGFR 19 del, 11 patients with 21-L858R. The median follow-up time was 22.47 months. The median PFS of the patients with or without EGFR amplification was 8.25 months and 10.67 months, respectively (log-rank test, P = 0.63). In multivariate analysis, EGFR amplification was not an independent prognosis factor for the patients receiving first-line TKIs [HR = 1.38, 95%CI (0.73–2.58), P = 0.321]. Subgroup analysis revealed that EGFR amplification is a risk factor for progression in the brain metastasis population. [HR = 2.28, 95%CI (1.01, 5.14), P = 0.047]. Conclusion EGFR amplification is not an independent prognosis factor for PFS in advanced non-squamous NSCLC patients receiving first-line TKIs. However, it is an independent risk factor for PFS in the brain metastasis population.https://doi.org/10.1186/s12885-022-10390-0Non-small cell lung cancerEGFR amplificationTyrosine kinase inhibitorsProgression-free survivalEGFR mutation |
| spellingShingle | Duanyang Peng Pingan Liang Congying Zhong Peng Xu Yanqing He Yuxi Luo Xia Wang Anwen Liu Zhimin Zeng Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study BMC Cancer Non-small cell lung cancer EGFR amplification Tyrosine kinase inhibitors Progression-free survival EGFR mutation |
| title | Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study |
| title_full | Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study |
| title_fullStr | Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study |
| title_full_unstemmed | Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study |
| title_short | Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study |
| title_sort | effect of egfr amplification on the prognosis of egfr mutated advanced non small cell lung cancer patients a prospective observational study |
| topic | Non-small cell lung cancer EGFR amplification Tyrosine kinase inhibitors Progression-free survival EGFR mutation |
| url | https://doi.org/10.1186/s12885-022-10390-0 |
| work_keys_str_mv | AT duanyangpeng effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy AT pinganliang effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy AT congyingzhong effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy AT pengxu effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy AT yanqinghe effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy AT yuxiluo effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy AT xiawang effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy AT anwenliu effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy AT zhiminzeng effectofegframplificationontheprognosisofegfrmutatedadvancednonsmallcelllungcancerpatientsaprospectiveobservationalstudy |